Abstract Library

#2164 A Case of Carcinoid Induced Heart Disease

Introduction: Carcinoid Heart disease is a common disease with neuroendocrine malignancies that invade the liver due to the paraneoplastic effects of vasoactive substances such as 5-hydroxytryptamine, histamine and tachykinins released by malignant cells rather than any direct metastatic involvement of the heart.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ashraff S

Authors: Ashraff S, MacGowan G, Perros P, James A,

Keywords: Carcinoid, Heart disease, heart valves,

#1942 Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial

Introduction: TELECAST assessed telotristat ethyl (TE), a tryptophan hydroxylase inhibitor, in patients (pts) with carcinoid syndrome (CS) with ≥1 CS symptom/sign and a mean 2.5 bowel movements (BMs) per day. Pts were somatostatin analog treated (89%), with gastrointestinal (90%; [diarrhea, 70%]) and cardiac disorders (42%), including carcinoid heart disease. At Week (W) 12, TE (250 and 500 mg 3×/day; tid) significantly reduced urinary 5-hydroxyindoleacetic acid (u5-HIAA) and BMs/day vs placebo (pbo) (p≤0.008). After W12, pts crossed over to an open-label extension (OLE) with TE 500 mg tid (W13–48).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Benavent M, Perros P, Srirajaskanthan R, Warner R,

Keywords: serotonin, safety,

#899 Evaluation of the Clinical Utility of Plasma Biomarkers in Diagnosis of Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NETs) are rare cancers that usually develop in the gastroenterohepatic system. Diagnostic workup of these tumors includes measurement of plasma levels of marker peptides. Clinical experience suggests that these markers may be misleading if used before histological or imaging evidence of a NET is available.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lunberg-Adams M

Authors: Lunberg-Adams M, James A, Perros P,

Keywords: chromogranin A, neurokinin A, pancreatic polypeptide, neuroendocrine tumor diagnosis,

#33 Survival of Neuroendocrine Tumour Patients in Newcastle NHS Foundation Trust

Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, with an incidence of 2-2.4 per 100,000, which derive from the neurones and epithelial cells of the diffuse neuroendocrine system. Neuropeptide-secreting NETs may present with overt clinical symptoms including abdominal pain, flushing and diarrhoea, whereas non-functioning NETs may be asymptomatic or present with obstructive symptoms. In Newcastle NHS Foundation Trust, NET patients are managed with a multi-disciplinary approach, according to UK and European NET guidelines.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Hearn K, Teo L, Bernstone G, Johnson S, Perros P,

Keywords: neuroendocrine tumor, survival, Ki-67 proliferation index, metastatic disease,